Eric B. Nonnecke

Eric B. Nonnecke

Auto-generated profile, based on publicly available information

Eric B. Nonnecke

Department of Microbiology and Immunology, School of Medicine, University of California-Davis, Davis, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2021 in Science
Verified
Journal Article
Closed access
PDF file
ENElisabeth E. L. Nyström
Elisabeth E. L. Nyström
BMBeatriz Martinez-Abad
Beatriz Martinez-Abad
LALiisa Arike
Liisa Arike
GBGeorge M. H. Birchenough
George M. H. Birchenough
ENEric B. Nonnecke
Eric B. Nonnecke
MJMalin E. V. Johansson
Malin E. V. Johansson
Goblet cell diversity: An adult human has a gut surface area averaging 30 square meters that is bombarded daily by xenobiotics and microorganisms. Mucus synthesized by goblet cells supplies a protective barrier coating. Nyström et al. discovered that goblet cells are not all the same along the length of the gut; rather, they form different functional populations depending on location. Small-intestine mucus is laced with antimicrobial peptides and is permeable to small molecules; downstream, thicker mucus is generated that excludes bacteria and xenobiotics. Mucus oozes in thick plumes from goblet cells within the crypts to shield the stem cell niche. Between the crypts lie highly differentiated goblet cells producing permeable mucus. Together, both types of mucus form a network that shelters the gut epithelium. If, however, the intercrypt goblet cells become dysfunctional, the exposed epithelium is exposed to bacteria and vulnerable to developing colitis. Science , this issue p. eabb1590

22 December 2022 in Nature Biomedical Engineering
Verified
Journal Article
Open access
PDF file
RWRuyi Wang
Ruyi Wang
SCShijie Cao
Shijie Cao
MBMohamed Elfatih H. Bashir
Mohamed Elfatih H. Bashir
LHLauren A. Hesser
Lauren A. Hesser
YSYanlin Su
Yanlin Su
CNCathryn R. Nagler
Cathryn R. Nagler
The microbiome modulates host immunity and aids the maintenance of tolerance in the gut, where microbial and food-derived antigens are abundant. Yet modern dietary factors and the excessive use of antibiotics have contributed to the rising incidence of food allergies, inflammatory bowel disease and other non-communicable chronic diseases associated with the depletion of beneficial taxa, including butyrate-producing Clostridia. Here we show that intragastrically delivered neutral and negatively charged polymeric micelles releasing butyrate in different regions of the intestinal tract restore barrier-protective responses in mouse models of colitis and of peanut allergy. Treatment with the butyrate-releasing micelles increased the abundance of butyrate-producing taxa in Clostridium cluster XIVa, protected mice from an anaphylactic reaction to a peanut challenge and reduced disease severity in a T-cell-transfer model of colitis. By restoring microbial and mucosal homoeostasis, butyrate-releasing micelles may function as an antigen-agnostic approach for the treatment of allergic and inflammatory diseases.

18 June 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ENEric B. Nonnecke
Eric B. Nonnecke
PCPatricia A. Castillo
Patricia A. Castillo
ADAmanda E. Dugan
Amanda E. Dugan
FAFaisal Almalki
Faisal Almalki
MUMark A. Underwood
Mark A. Underwood
CBCharles Bevins
Charles Bevins
Intelectins are ancient carbohydrate binding proteins, spanning chordate evolution and implicated in multiple human diseases. Previous GWAS have linked SNPs in ITLN1 (also known as omentin) with susceptibility to Crohn's disease (CD); however, analysis of possible functional significance of SNPs at this locus is lacking. Using the Ensembl database, pairwise linkage disequilibrium (LD) analyses indicated that several disease-associated SNPs at the ITLN1 locus, including SNPs in CD244 and Ly9, were in LD. The alleles comprising the risk haplotype are the major alleles in European (67%), but minor alleles in African superpopulations. Neither ITLN1 mRNA nor protein abundance in intestinal tissue, which we confirm as goblet-cell derived, was altered in the CD samples overall nor when samples were analyzed according to genotype. Moreover, the missense variant V109D does not influence ITLN1 glycan binding to the glycan β-D-galactofuranose or protein–protein oligomerization. Taken together, our data are an important step in defining the role(s) of the CD-risk haplotype by determining that risk is unlikely to be due to changes in ITLN1 carbohydrate recognition, protein oligomerization, or expression levels in intestinal mucosa. Our findings suggest that the relationship between the genomic data and disease arises from changes in CD244 or Ly9 biology, differences in ITLN1 expression in other tissues, or an alteration in ITLN1 interaction with other proteins.

19 February 2022 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
ENEric B. Nonnecke
Eric B. Nonnecke
PCPatricia A. Castillo
Patricia A. Castillo
MJMalin E. V. Johansson
Malin E. V. Johansson
EHEdward J. Hollox
Edward J. Hollox
BSBo Shen
Bo Shen
CBCharles Bevins
Charles Bevins
Intelectins (intestinal lectins) are highly conserved across chordate evolution and have been implicated in various human diseases, including Crohn's disease (CD). The human genome encodes two intelectin genes, intelectin‐1 ( ITLN1 ) and intelectin‐2 ( ITLN2 ). Other than its high sequence similarity with ITLN1, little is known about ITLN2. To address this void in knowledge, we report that ITLN2 exhibits discrete, yet notable differences from ITLN1 in primary structure, including a unique amino terminus, as well as changes in amino acid residues associated with the glycan‐binding activity of ITLN1. We identified that ITLN2 is a highly abundant Paneth cell‐specific product, which localizes to secretory granules, and is expressed as a multimeric protein in the small intestine. In surgical specimens of ileal CD, ITLN2 mRNA levels were reduced approximately five‐fold compared to control specimens. The ileal expression of ITLN2 was unaffected by previously reported disease‐associated variants in ITLN2 and CD‐associated variants in neighboring ITLN1 as well as NOD2 and ATG16L1 . ITLN2 mRNA expression was undetectable in control colon tissue; however, in both ulcerative colitis (UC) and colonic CD, metaplastic Paneth cells were found to express ITLN2. Together, the data reported establish the groundwork for understanding ITLN2 function(s) in the intestine, including its possible role in CD.

18 January 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
Shasta McMillenShasta McMillen
Shasta McMillen
STSydney Thomas
Sydney Thomas
ELEmily Liang
Emily Liang
ENEric B. Nonnecke
Eric B. Nonnecke
CSCarolyn Slupsky
Carolyn Slupsky
BLBo Lars Lonnerdal
Bo Lars Lonnerdal
The gut microbiota is implicated in the adverse developmental outcomes of postnatal iron supplementation. To generate hypotheses on how changes to the gut microbiota by iron adversely affect development, and to determine whether the form of iron influences microbiota outcomes, we characterized gut microbiome and metabolome changes in Sprague-Dawley rat pups given oral supplements of ferrous sulfate (FS), ferrous bis-glycinate chelate (FC), or vehicle control (CON) on postnatal day (PD) 2–14. Iron supplementation reduced microbiome alpha-diversity (p < 0.0001) and altered short-chain fatty acids (SCFAs) and trimethylamine (TMA) in a form-dependent manner. To investigate the long-term effects of iron provision in early life, an additional cohort was supplemented with FS, FC, or CON until PD 21 and then weaned onto standard chow. At ~8 weeks of age, young adult (YA) rats that received FS exhibited more diverse microbiomes compared to CON (p < 0.05), whereas FC microbiomes were less diverse (p < 0.05). Iron provision resulted in 10,000-fold reduced abundance of Lactobacilli in pre-weanling and YA animals provided iron in early life (p < 0.0001). Our results suggest that in pre-weanling rats, supplemental iron form can generate differential effects on the gut microbiota and microbial metabolism that persist into adulthood.

21 September 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
Shasta McMillenShasta McMillen
Shasta McMillen
ENEric B. Nonnecke
Eric B. Nonnecke
BLBo Lars Lonnerdal
Bo Lars Lonnerdal
Iron supplements are frequently provided to infants in high-income countries despite low incidence of iron deficiency. There is growing concern regarding adverse health and development outcomes of excess iron provision in early life. Excess iron may directly damage developing organs through the formation of reactive oxygen species, alter systemic inflammatory signaling, and/or dysregulate trace mineral metabolism. To better characterize the in vivo effects of excess iron on development, we utilized a pre-weanling rat pup model. Lewis rat litters were culled to eight pups (four males and four females) and randomly assigned to daily supplementation groups receiving either vehicle control (CON; 10% w/v sucrose solution) or ferrous sulfate (FS) iron at one of the following doses: 10, 30, or 90 mg iron/kg body weight—FS-10, FS-30, and FS-90, respectively—from postnatal day (PD) 2 through 9. FS-90 litters, but not FS-30 or FS-10, failed to thrive compared to CON litters and had smaller brains on PD 10. Among the groups, FS-90 liver iron levels were highest, as were white blood cell counts. Compared to CON, circulating MCP-1 and liver zinc were increased in FS-90 pups, whereas liver copper was decreased. Growth defects due to excess FS provision in pre-weanling rats may be related to liver injury, inflammation, and altered trace mineral metabolism.